📣 VC round data is live. Check it out!

Prime Medicine Valuation Multiples

Discover revenue and EBITDA valuation multiples for Prime Medicine and similar public comparables like Ocugen, Cormedix, Aclaris Therapeutics, Sutro Biopharma and more.

Prime Medicine Overview

About Prime Medicine

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.


Founded

2019

HQ

United States

Employees

214

Financials (LTM)

Revenue: $10M
EBITDA: ($193M)

EV

$565M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Prime Medicine Financials

Prime Medicine reported last 12-month revenue of $10M and negative EBITDA of ($193M).

In the same LTM period, Prime Medicine generated $10M in gross profit, ($193M) in EBITDA losses, and had net loss of ($192M).

Revenue (LTM)


Prime Medicine P&L

In the most recent fiscal year, Prime Medicine reported revenue of $5M and EBITDA of ($201M).

Prime Medicine is unprofitable as of last fiscal year, with EBITDA margin of (4340%) and net margin of (4342%).

See analyst estimates for Prime Medicine
LTMLast FY202320242025202620272028
Revenue$10M$5M—$3M$5M
Gross Profit$10M————
Gross Margin100%————
EBITDA($193M)($201M)($187M)($196M)($201M)
EBITDA Margin(2033%)(4340%)—(6582%)(4340%)
EBIT Margin(2050%)(4498%)—(6787%)(4498%)
Net Profit($192M)($201M)($198M)($196M)($201M)
Net Margin(2020%)(4342%)—(6567%)(4342%)

Financial data powered by Morningstar, Inc.

Prime Medicine Stock Performance

Prime Medicine has current market cap of $626M, and enterprise value of $565M.

Market Cap Evolution


Prime Medicine's stock price is $3.46.

Prime Medicine share price decreased by 2.3% in the last 30 days, and increased by 193.6% in the last year.

Prime Medicine has an EPS (earnings per share) of $-1.11.

See more trading valuation data for Prime Medicine
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$565M$626M1.6%-2.3%-25.0%193.6%$-1.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Prime Medicine Valuation Multiples

Prime Medicine trades at 59.4x EV/Revenue multiple, and (2.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for Prime Medicine

EV / Revenue (LTM)


Prime Medicine Financial Valuation Multiples

As of May 5, 2026, Prime Medicine has market cap of $626M and EV of $565M.

Prime Medicine has a P/E ratio of (3.3x).

LTMLast FY202320242025202620272028
EV/Revenue59.4x121.9x—189.3x121.9x
EV/EBITDA(2.9x)(2.8x)(3.0x)(2.9x)(2.8x)
EV/EBIT(2.9x)(2.7x)(3.0x)(2.8x)(2.7x)
EV/Gross Profit59.4x————
P/E(3.3x)(3.1x)(3.2x)(3.2x)(3.1x)
EV/FCF(3.5x)(3.4x)(3.2x)(4.3x)(3.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Prime Medicine Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Prime Medicine Margins & Growth Rates

In the most recent fiscal year, Prime Medicine reported EBITDA margin of (4340%) and net margin of (4342%).

See estimated margins and future growth rates for Prime Medicine

Prime Medicine Margins

Last FY20242025202720282029
EBITDA Margin(4340%)(6582%)(4340%)
EBIT Margin(4498%)(6787%)(4498%)
Net Margin(4342%)(6567%)(4342%)
FCF Margin(3607%)(4363%)(3607%)

Prime Medicine Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth—55%
EBITDA Growth5%2%
EBIT Growth6%3%
Net Profit Growth(1%)3%
FCF Growth(25%)28%

Data powered by FactSet, Inc. and Morningstar, Inc.

Prime Medicine Operational KPIs

Prime Medicine's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.

Access forward-looking KPIs for Prime Medicine
LTMLast FY20242025202620272028
Rule of 40(1896%)———
Bessemer Rule of X(1689%)———
Revenue per Employee—$0.0M——
Opex per Employee—$1.0M——
G&A Expenses to Revenue—1130%1682%1130%
R&D Expenses to Revenue1644%3468%5206%3468%
Opex to Revenue—4598%6887%4598%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Prime Medicine Competitors

Prime Medicine competitors include Ocugen, Cormedix, Aclaris Therapeutics, Sutro Biopharma, Tempo Scan Pacific, Entrada Therapeutics, Abclon, Onconic Therapeutics, Agomab Therapeutics and Zevra Therapeutics.

Most Prime Medicine public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Ocugen146.0x185.5x(10.7x)—
Cormedix2.0x2.0x3.7x3.7x
Aclaris Therapeutics69.2x80.3x(7.8x)—
Sutro Biopharma5.0x6.5x(3.6x)(3.6x)
Tempo Scan Pacific0.5x—3.5x—
Entrada Therapeutics14.5x15.3x(2.4x)(2.3x)
Abclon183.4x—(52.9x)—
Onconic Therapeutics16.9x—63.3x—

This data is available for Pro users. Sign up to see all Prime Medicine competitors and their valuation data.

Start Free Trial

Prime Medicine Funding History

Before going public, Prime Medicine raised $385M in total equity funding, across 4 rounds.

Last private valuation of Prime Medicine was $1B, after raising $200M in July 2021 from ARCH Venture Partners, Arrive, Casdin Capital, and 9 other investors.


Prime Medicine Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Sep-24Strategic investmentBristol-Myers Squibb$55M—Prime Medicine, a biotech company developing precise gene editing therapies using Prime Editing technology, announced a strategic research collaboration and license agreement with Bristol Myers Squibb on September 30, 2024, focused on ex vivo T-cell therapies for hematology, immunology, and oncology. Under the terms, Prime Medicine receives $55 million upfront cash and $55 million in equity investment, totaling $110 million upfront, with potential milestones exceeding $3.5 billion, including up to $1.4 billion in development and over $2.1 billion in commercialization milestones, plus royalties on net sales. Bristol Myers Squibb leads development, manufacturing, and commercialization, leveraging Prime's Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE) for optimized reagents on select targets. Simultaneously, Prime Medicine reprioritized its pipeline to extend its cash runway into the first half of 2026, addressing prior concerns about going concern raised in a June 2024 SEC filing. The company narrowed focus to high-value programs: two ex vivo autologous hematopoietic stem cell therapies for chronic granulomatous disease (with initial clinical data expected in 2025), a Wilson's disease program for liver (potential clinic entry 2026), and cystic fibrosis supported by foundation funding. Programs in glycogen storage disease 1b, retinitis pigmentosa, Friedreich's ataxia, and others were paused or shifted to partnerships, without planned layoffs. This deal validates Prime's technology amid a challenging biotech funding environment, with shares rising ~40% post-announcement but trading below IPO levels. Prime, co-founded by gene editing pioneer David Liu, continues advancing investigational programs in core areas while seeking additional non-dilutive partnerships to bolster its balance sheet.
Jan-24Series ACystic Fibrosis Foundation$15M—Prime Medicine is a biotechnology company developing prime editing gene therapies to correct genetic diseases, particularly cystic fibrosis. The company received up to $15 million in funding from the Cystic Fibrosis Foundation under an agreement announced January 25, 2024, with an initial $6 million upfront payment and additional tranches contingent on achieving preclinical milestones. The funding was designated to support development of Prime Editors—specifically hotspot and PASSIGE-based approaches—designed to correct CFTR mutations that cause cystic fibrosis. Prime Medicine planned to leverage this funding for delivery optimizations and early research to address the approximately 15% of CF patients who cannot clinically benefit from or tolerate existing treatments. The CF Foundation's investment built on its broader $500 million Path to a Cure research initiative aimed at developing genetic therapies for cystic fibrosis.
Jul-21Series BARCH Venture Partners; Arrive; Casdin Capital; Cormorant Asset Management; F-Prime; GV; Moore Strategic Ventures; Newpath Management; PSP Investments; Redmile Group; Samsara BioCapital; T. Rowe Price$200M$1BPrime Medicine, a Cambridge, Massachusetts-based biotech company co-founded by David Liu, launched on July 13, 2021, with $315 million in total financing, comprising a $115 million Series A and a $200 million Series B. The Series B included investors such as ARCH Venture Partners, F-Prime Capital, GV, Newpath Partners, Casdin Capital, Cormorant Asset Management, Moore Strategic Ventures, PSP Investments, Redmile Group, Samsara BioCapital, and T. Rowe Price, matching the query details. The company develops Prime Editing, a next-generation gene editing technology likened to a DNA word processor for precise 'search and replace' corrections without double-strand breaks, targeting diseases like sickle cell disease, liver diseases, hearing loss, neuromuscular conditions, Duchenne muscular dystrophy, and cystic fibrosis, with 18 preclinical programs. Funds from the rounds support building the company, advancing toward clinical indications, expanding the platform, and enhancing Prime Editing capabilities, with plans to employ over 100 people by end-2021. Prime Medicine had established preclinical proof-of-concept in vivo for sickle cell disease, partnered with Beam Therapeutics. Keith Gottesdiener, a biotech veteran from Rhythm Pharmaceuticals, serves as president and CEO. Prime Medicine went public in October 2022, raising $175 million in an upsized IPO at $17 per share for a $1.7 billion fully diluted market value, after confidentially filing in December 2021. This followed the funding rounds amid a slowing IPO market for biotechs.
Oct-19Series AARCH Venture Partners; Arrive; F-Prime; GV; Newpath Management$115M—Prime Medicine is a biotechnology company focused on developing Prime Editing, a next-generation gene editing technology described as a precise 'search-and-replace' method for DNA to address genetic diseases without double-strand breaks. Founded by Harvard biochemist David Liu and co-founder Andrew Anzalone, the company began operations in summer 2020 and emerged from stealth in July 2021. It holds a license from the Broad Institute for prime editing technology under an inclusive innovation model and maintains a collaboration with Beam Therapeutics for sharing research, expertise, and IP in areas like testing and manufacturing. The company launched with $315 million in total financing, comprising a $115 million Series A round led by ARCH Venture Partners, F-Prime Capital, GV, and Newpath Partners (also listed as Arrive or Newpath Management in some sources), followed by a $200 million Series B approximately nine months later with expanded investors including Casdin Capital, Cormorant, and others. Funds were allocated to build the company, advance preclinical programs toward clinical indications, expand platform capabilities, and grow to over 100 employees by end-2021. Prime Medicine has progressed with an 18-program pipeline targeting genetic diseases, led by CEO Keith Gottesdiener, a biotech veteran from Rhythm Pharmaceuticals. Later developments include a 2022 IPO raising $175 million at a $1.7 billion fully diluted valuation, strategic partnerships like a Bristol-Myers Squibb deal with $55 million upfront and equity plus milestones over $3.5 billion, and Cystic Fibrosis Foundation funding up to $39 million.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Prime Medicine

When was Prime Medicine founded?Prime Medicine was founded in 2019.
Where is Prime Medicine headquartered?Prime Medicine is headquartered in United States.
How many employees does Prime Medicine have?As of today, Prime Medicine has over 214 employees.
Who is the CEO of Prime Medicine?Prime Medicine's CEO is Allan Reine.
Is Prime Medicine publicly listed?Yes, Prime Medicine is a public company listed on Nasdaq.
What is the stock symbol of Prime Medicine?Prime Medicine trades under PRME ticker.
When did Prime Medicine go public?Prime Medicine went public in 2022.
Who are competitors of Prime Medicine?Prime Medicine main competitors include Ocugen, Cormedix, Aclaris Therapeutics, Sutro Biopharma, Tempo Scan Pacific, Entrada Therapeutics, Abclon, Onconic Therapeutics, Agomab Therapeutics, Zevra Therapeutics.
What is the current market cap of Prime Medicine?Prime Medicine's current market cap is $626M.
What is the current revenue of Prime Medicine?Prime Medicine's last 12 months revenue is $10M.
What is the current revenue growth of Prime Medicine?Prime Medicine revenue growth (NTM/LTM) is 138%.
What is the current EV/Revenue multiple of Prime Medicine?Current revenue multiple of Prime Medicine is 59.4x.
Is Prime Medicine profitable?No, Prime Medicine is not profitable.
What is the current EBITDA of Prime Medicine?Prime Medicine has negative EBITDA and is not profitable.
What is Prime Medicine's EBITDA margin?Prime Medicine's last 12 months EBITDA margin is (2033%).
What is the current EV/EBITDA multiple of Prime Medicine?Current EBITDA multiple of Prime Medicine is (2.9x).
What is the current FCF of Prime Medicine?Prime Medicine's last 12 months FCF is ($161M).
What is Prime Medicine's FCF margin?Prime Medicine's last 12 months FCF margin is (1691%).
What is the current EV/FCF multiple of Prime Medicine?Current FCF multiple of Prime Medicine is (3.5x).
How many companies Prime Medicine has acquired to date?Prime Medicine hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Prime Medicine has invested to date?Prime Medicine hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Prime Medicine

Lists including Prime Medicine

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial